A Study of Efgartigimod PH20 SC in Children Between 2 and Le... | Clinical Trial | StuddyBuddy@endsection A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT06392386

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Conditions: Generalized Myasthenia Gravis

Sex: All
Ages: 2 Years – 17 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 12
Sponsor: argenx

Location: Carolinas HealthCare System Neurosciences Institute - Neurology Charlotte North Carolina

Summary

The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \

Eligibility Criteria

Inclusion Criteria: * The participant (and/or their legally authorized representative) understands the requirements of the study and is capable of providing written informed consent/assent and complying with protocol requirements * The participant is aged 2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06392386). StuddyBuddy aggregates publicly available trial information.